Factor VIII Gene Therapy Study in Patients With Hemophilia A



Status:Recruiting
Conditions:Anemia, Hematology
Therapuetic Areas:Hematology
Healthy:No
Age Range:18 - Any
Updated:4/4/2019
Start Date:November 7, 2018
End Date:August 30, 2025
Contact:Bayer Clinical Trials Contact
Email:clinical-trials-contact@bayer.com
Phone:(+) 1-888-8422937

Use our guide to learn which trials are right for you!

A Phase 1/2 Open-label Safety and Dose-finding Study of BAY2599023 (DTX201), an Adeno-associated Virus (AAV) hu37-mediated Gene Transfer of B-domain Deleted Human Factor VIII, in Adults With Severe Hemophilia A

The purpose of this study is to determine the safety and tolerability of the factor VIII gene
transfer treatment with BAY 2599023 (DTX201) in individuals with severe hemophilia A.


Inclusion Criteria:

- Males age 18 years or older

- Confirmed diagnosis of hemophilia A as evidenced by their medical history with plasma
FVIII activity levels < 1% of normal or at screening.

- Have >150 exposure days (EDs) to FVIII concentrates (recombinant or plasma-derived).

If on prophylaxis, should be able and willing to stop prophylactic treatment at specified
time points throughout the study or If on-demand: should have had > 4 bleeding events in
the last 52 weeks

- Agree to use reliable barrier contraception

Exclusion Criteria:

- History of allergic reaction to any FVIII product

- Current evidence of measurable inhibitor against factor VIII, as assessed by the
central laboratory and/or prior history of inhibitors to FVIII protein

- Evidence of active hepatitis B or C

- Currently on antiviral therapy for hepatitis B or C

- Significant underlying liver disease

- Serological evidence of HIV-1 or HIV-2 with CD4 counts ≤200/mm*3; HIV+ and stable
participants with CD4 count >200/mm*3 and undetectable viral load are eligible to
enroll

- Detectable antibodies reactive with AAVhu37capsid

- Participant with another bleeding disorder that is different from hemophilia A (e.g.,
von Willebrand disease, hemophilia B)

- Participated in a gene transfer trial within the last 52 weeks or in a clinical trial
with an investigational product within the last 12 weeks
We found this trial at
6
sites
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
Ann Arbor, MI 48109Bus: -
Ann Arbor, Michigan 48109
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
1 Children's Way
Little Rock, Arkansas 72202
(501) 364-1100
Arkansas Children's Hospital Arkansas Children's Hospital (ACH) is the only pediatric medical center in Arkansas...
?
mi
from
Little Rock, AR
Click here to add this to my saved trials
Madison, Wisconsin 53706
(608) 263-2400
University of Wisconsin-Madison In achievement and prestige, the University of Wisconsin-Madison has long been recognized...
?
mi
from
Madison, WI
Click here to add this to my saved trials
San Bernardino, California 92408
?
mi
from
San Bernardino, CA
Click here to add this to my saved trials
?
mi
from
Sofia,
Click here to add this to my saved trials